Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function
Open accessThe DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers in western countries, with a median survival of 6 months and an extremely low percentage of long-term surviving patients. KRAS mutations are known to be a driver event of PDAC, but targeting mutant KRAS has proved challenging. Targeting oncogene-driven signalling pathways is a clinically validated approach for several devastating diseases. Still, despite marked tumour shrinkage, the frequency of relapse indicates that a fraction of tumour cells survives shut down of oncogenic signalling. Here we explore the role of mutant KRAS in PDAC maintenance using a recently developed inducible mouse model of mutated Kras (Kras(G12D), herein KRas) in a p53(LoxP/WT) background. We demonstrate that a subpopulation of dormant tumour cells surviving oncogene ablation (surviving cells) and responsible for tumour relapse has features of cancer stem cells and relies on oxidative phosphorylation for survival. Transcriptomic and metabolic analyses of surviving cells reveal prominent expression of genes governing mitochondrial function, autophagy and lysosome activity, as well as a strong reliance on mitochondrial respiration and a decreased dependence on glycolysis for cellular energetics. Accordingly, surviving cells show high sensitivity to oxidative phosphorylation inhibitors, which can inhibit tumour recurrence. Our integrated analyses illuminate a therapeutic strategy of combined targeting of the KRAS pathway and mitochondrial respiration to manage pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Prior studies have demonstrated that genetic ablation of KRAS expression leads to cell cycle arrest and death in cell lines and potent tumor regressions in animal models of PDAC (5–7).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with this notion, other complex I inhibitors have shown efficacy as anti-tumor agents (Appleyard et al., 2012; Schockel et al., 2015) and may show selective toxicity against oncogene-ablation resistant cells (Viale et al., 2014) and cancer stem cells (Sancho et al., 2015).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Viale et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recurrent theme in studies on cancer progression is the increased reliance of cancer cells on OXPHOS in advanced stages of disease.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast to the proliferating bulk of a tumor, accumulating evidence suggests that quiescent subpopulations of tumor cells are markedly less glycolytic and exhibit higher dependence on oxidative phosphorylation, as well as elevated expression of mitochondrial respiratory components.”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Viale et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a mouse pancreatic cancer model, ablating oncogenic Kras from established tumors revealed a fraction of cells that survive and eventually propagate.”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [103]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Autophagy regulates lipid metabolism
Singh, R., Kaushik, S., Wang, Y., Xiang, Y., Novak, I., Komatsu, M., Tanaka, K., Cuervo, A. M., & Czaja, M. J. (2009) · Nature · doi:10.1038/nature07976 · Cited by 3,975
Self-citationTransmission Electron Microscopy
Williams, D. B., & Carter, C. B. (2009) · Springer eBooks · doi:10.1007/978-0-387-76501-3 · Cited by 3,963
Identification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Updated research nosology for HIV-associated neurocognitive disorders
Antinori, A., Arendt, G., Becker, J. T., Brew, B. J., Byrd, D. A., Cherner, M., Clifford, D. B., Cinque, P., Epstein, L. G., Goodkin, K., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000287431.88658.8b · Cited by 2,630
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
Self-citationHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., et al. (2013) · Nature · doi:10.1038/nature12040 · Cited by 1,990
Self-citation
Cited by
Items 201–300 of 1,000
Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy
Li, Y., Liu, J., Chen, Y., Weichselbaum, R. R., & Lin, W. (2024) · Advanced Science · doi:10.1002/advs.202310309 · Cited by 179
Zhou, C., Sun, H., Zheng, C., Gao, J., Fu, Q., Hu, N., Shao, X., Zhou, Y., Xiong, J., Nie, K., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0196-z · Cited by 135
The biological underpinnings of therapeutic resistance in pancreatic cancer
Beatty, G. L., Werba, G., Lyssiotis, C. A., & Simeone, D. M. (2021) · Genes & Development · doi:10.1101/gad.348523.121 · Cited by 159
Self-citationMitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
Stuani, L., Sabatier, M., Wang, F., Poupin, N., Bosc, C., Saland, E., Castelli, F. A., Gales, L., Montersino, C., Boët, E., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200924 · Cited by 155
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer
Genovese, G., Carugo, A., Tepper, J., Robinson, F. S., Li, L., Svelto, M., Nezi, L., Corti, D., Minelli, R., Pettazzoni, P., et al. (2017) · Nature · doi:10.1038/nature21064 · Cited by 131
Self-citationDelivery of drugs and macromolecules to the mitochondria for cancer therapy
Lu, P., Bruno, B. J., Rabenau, M., & Lim, C. S. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.023 · Cited by 135
Metabolic reprogramming and its clinical implication for liver cancer
Yang, F., Hilakivi-Clarke, L. A., Shaha, A., Wang, Y., Wang, X., Deng, Y., Lai, J., & Kang, N. (2023) · Hepatology · doi:10.1097/hep.0000000000000005 · Cited by 197
Self-citationNew Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00953 · Cited by 129
“Early evidence suggested that not all KRAS-mutant tumor cells are dependent on KRAS (18, 19), and that some KRAS-mutant cancer cells, including lung (20) and pancreatic cancer cells (21, 22), can survive in the absence of the KRAS oncogene.”
BackgroundMudassar, F., Shen, H., O’Neill, G., & Hau, E. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01724-6 · Cited by 129
Simultaneous DNA and RNA Mapping of Somatic Mitochondrial Mutations across Diverse Human Cancers
Stewart, J. B., Alaei-Mahabadi, B., Sabarinathan, R., Samuelsson, T., Gorodkin, J., Gustafsson, C. M., & Larsson, E. (2015) · PLOS Genetics · doi:10.1371/journal.pgen.1005333 · Cited by 128
Zhao, Y., Dong, Q., Li, J., Zhang, K., Qin, J., Zhao, J., Sun, Q., Wang, Z., Wartmann, T., Jauch, K. W., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.08.002 · Cited by 136
Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
Lee, M., Hirpara, J. L., Eu, J.-Q., Sethi, G., Wang, L., Goh, B.-C., & Wong, A. L. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101073 · Cited by 127
Koundinya, M., Sudhalter, J., Courjaud, A., Lionne, B., Touyer, G., Bonnet, L., Menguy, I., Schreiber, I., Perrault, C., Vougier, S., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.03.005 · Cited by 125
Self-citationRecent insights into the biology of pancreatic cancer
Yao, W., Maitra, A., & Ying, H. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102655 · Cited by 144
Self-citationMitochondrial dynamics and cancer
Maycotte, P., Marín‐Hernández, Á., Goyri-Aguirre, M., Anaya-Ruíz, M., Reyes‐Leyva, J., & Cortés-Hernández, P. (2017) · Tumor Biology · doi:10.1177/1010428317698391 · Cited by 134
Cancer Metabolism Drives a Stromal Regenerative Response
Schwörer, S., Vardhana, S. A., & Thompson, C. B. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.015 · Cited by 123
Glucose Metabolism in Pancreatic Cancer
Liang, Y., Raj, P. S., Yao, W., & Ying, H. (2019) · Cancers · doi:10.3390/cancers11101460 · Cited by 145
Self-citationGiulietti, M., Occhipinti, G., Principato, G., & Piva, F. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0283-7 · Cited by 126
Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR
Deng, P., & Haynes, C. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.05.002 · Cited by 128
Mitochondria as a target in cancer treatment
Liu, Y., & Shi, Y. (2020) · MedComm · doi:10.1002/mco2.16 · Cited by 130
Bosc, C., Saland, E., Bousard, A., Gadaud, N., Sabatier, M., Cognet, G., Farge, T., Boët, E., Gotanègre, M., Aroua, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00264-y · Cited by 136
Self-citationEvolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer
Dasgupta, B., & Chhipa, R. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.007 · Cited by 118
Roles of mitochondria in the hallmarks of metastasis
Scheid, A. D., Beadnell, T. C., & Welch, D. R. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01125-8 · Cited by 137
Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches
Klein, K., He, K., Younes, A. I., Barsoumian, H. B., Chen, D., Ozgen, T., Mosaffa, S., Patel, R. R., Gu, M., Novaes, J., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573326 · Cited by 117
The Effect of Oxidative Phosphorylation on Cancer Drug Resistance
Zhao, Z., Mei, Y., Wang, Z., & He, W. (2022) · Cancers · doi:10.3390/cancers15010062 · Cited by 115
Zhang, H., Badur, M. G., Divakaruni, A. S., Parker, S. J., Jäger, C., Hiller, K., Murphy, A. N., & Metallo, C. M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.06.102 · Cited by 117
Metabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 117
Self-citationMitochondria on the move: Horizontal mitochondrial transfer in disease and health
Dong, L., Rohlena, J., Zobalová, R., Nahácka, Z., Rodriguez, A., Berridge, M. V., & Neužil, J. (2023) · The Journal of Cell Biology · doi:10.1083/jcb.202211044 · Cited by 127
The double-edged sword of AMPK signaling in cancer and its therapeutic implications
Jeon, S.-M., & Hay, N. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0549-z · Cited by 112
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“Another common feature of DTP cells is the ability to sustain their metabolism with alternative sources of nutrients such as autophagy or fatty acid oxidation (FAO) pathways [27,35,36].”
BackgroundCommander, R., Wei, C., Sharma, A., Mouw, J. K., Burton, L. J., Summerbell, E. R., Mahboubi, D., Peterson, R. J., Konen, J. M., Zhou, W., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15219-7 · Cited by 125
Porporato, P. E., Payen, V. L., Baselet, B., & Sonveaux, P. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2100-2 · Cited by 121
Lyons, A., Coleman, M. F., Riis, S., Favre, C., O’Flanagan, C. H., Zhdanov, A. V., Papkovsky, D. B., Hursting, S. D., & O’Connor, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.792838 · Cited by 116
Rivadeneira, D. B., Caino, M. C., Seo, J. H., Angelin, A., Wallace, D. C., Languino, L. R., & Altieri, D. C. (2015) · Science Signaling · doi:10.1126/scisignal.aab1624 · Cited by 121
Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context
Kerk, S. A., Lin, L., Myers, A. L., Sutton, D. J., Andren, A., Sajjakulnukit, P., Zhang, L., Zhang, Y., Jiménez, J. A., Nelson, B. S., et al. (2022) · eLife · doi:10.7554/elife.73245 · Cited by 108
Self-citationGenetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine
Knudsen, E. S., O’Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 107
Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models
Heinrich, M. A., Mostafa, A. M. R. H., Morton, J. P., Hawinkels, L. J. A. C., & Prakash, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.018 · Cited by 126
Edwards, D. K., Watanabe-Smith, K., Rofelty, A., Damnernsawad, A., Laderas, T., Lamble, A., Lind, E. F., Kaempf, A., Mori, M., Rosenberg, M., et al. (2019) · Blood · doi:10.1182/blood-2018-03-838946 · Cited by 106
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13086-5 · Cited by 106
Genini, D., Brambilla, L., Laurini, E., Merulla, J., Civenni, G., Pandit, S., D'Antuono, R., Perez, L., Levy, D. E., Pricl, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615730114 · Cited by 106
Current and future perspectives of functional metabolomics in disease studies–A review
Yan, M., & Xu, G. (2018) · Analytica Chimica Acta · doi:10.1016/j.aca.2018.04.006 · Cited by 105
Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy
Caino, M. C., & Altieri, D. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0460 · Cited by 105
Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape
Sarkar, T., Dhar, S., & Sa, G. (2021) · Current Research in Immunology · doi:10.1016/j.crimmu.2021.08.002 · Cited by 114
Zhu, W., Wang, J., Liu, X., Yanbin, X., Zhai, R., Zhang, J., Wang, M., Wang, M., & Liu, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05157-1 · Cited by 108
Cancer resistance and metastasis are maintained through oxidative phosphorylation
Uslu, C., Kapan, E., & Lyakhovich, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216705 · Cited by 125
Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics
Navarro, P., Bueno, M. J., Zagorac, I., Mondejar, T., Sanchez, J., Mourón, S., Muñoz, J., Gómez-López, G., Jimenez-Renard, V., Mulero, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.052 · Cited by 102
“1.1-treated tumors behaved like vehicle-treated tumors; data are not shown unless required for experimental data layout, because the adaptive changes regarding resistance to mAb antiangiogenic treatment have been described elsewhere (Chung et al., 2013; Xu et al., 2014).”
BackgroundInfluentialAberrant lipid metabolism as an emerging therapeutic strategy to target cancer stem cells
Visweswaran, M., Arfuso, F., Warrier, S. R., & Dharmarajan, A. (2019) · Stem Cells · doi:10.1002/stem.3101 · Cited by 108
Bhola, N. E., Jansen, V. M., Koch, J. P., Li, H., Formisano, L., Williams, J. A., Grandis, J. R., & Arteaga, C. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1640-t · Cited by 115
Pancreatic cancer: Current research and future directions
Falasca, M., Kim, M., & Casari, I. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.01.001 · Cited by 107
Mitochondrial Fission and Fusion in Tumor Progression to Metastasis
Boulton, D. P., & Caino, M. C. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.849962 · Cited by 114
Wang, X., Li, Y., Li, Z., Lin, S., Wang, H., Sun, J., Lan, C., Wu, L., Sun, D., Huang, C., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3230 · Cited by 118
Self-citationChoi, H.-J., Jhe, Y.-L., Kim, J., Lim, J. Y., Lee, J. E., Shin, M., & Cheong, J. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101589 · Cited by 113
Digging deeper through glucose metabolism and its regulators in cancer and metastasis
Ghanavat, M., Shahrouzian, M., Zayeri, Z. D., Banihashemi, S., Kazemi, S. M., & Saki, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118603 · Cited by 105
Wang, Z., Hausmann, S., Lyu, R., Li, T., Lofgren, S., Flores, N. M., Fuentes, M. E., Caporicci, M., Yang, Z., Meiners, M. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.014 · Cited by 109
Self-citationBacci, M., Giannoni, E., Fearns, A., Ribas, R., Gao, Q., Taddei, M. L., Pintus, G., Dowsett, M., Isacke, C. M., Martin, L.-A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2038 · Cited by 99
Imaging metabolic heterogeneity in cancer
Sengupta, D., & Pratx, G. (2016) · Molecular Cancer · doi:10.1186/s12943-015-0481-3 · Cited by 98
Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis
Palorini, R., Votta, G., Pirola, Y., Vitto, H. D., Palma, S. D., Airoldi, C., Vasso, M., Ricciardiello, F., Lombardi, P. P., Cirulli, C., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1005931 · Cited by 107
Aguilar, E., Marin de Mas, I., Zodda, E., Marin, S., Morrish, F., Selivanov, V., Meca-Cortés, Ó., Delowar, H., Pons, M., Izquierdo, I., et al. (2016) · Stem Cells · doi:10.1002/stem.2286 · Cited by 96
Phenotypic Plasticity and Cell Fate Decisions in Cancer: Insights from Dynamical Systems Theory
Jia, D., Jolly, M. K., Kulkarni, P., & Levine, H. (2017) · Cancers · doi:10.3390/cancers9070070 · Cited by 96
Crosstalk between autophagy and metabolic regulation of cancer stem cells
El-Hout, M., Cosialls, E., Mehrpour, M., & Hamaï, A. (2020) · Molecular Cancer · doi:10.1186/s12943-019-1126-8 · Cited by 102
Daurio, N. A., Tuttle, S. W., Worth, A. J., Song, E. Y., Davis, J. M., Snyder, N. W., Blair, I. A., & Koumenis, C. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2197 · Cited by 96
Sohoni, S. S., Ghosh, P., Wang, T., Kalainayakan, S. P., Vidal, C., Dey, S., Konduri, P. C., & Li, Z. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2156 · Cited by 100
Mitohormesis Primes Tumor Invasion and Metastasis
Kenny, T. C., Craig, A. J., Villanueva, A., & Germain, D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.095 · Cited by 104
Dijk, S. N., Protasoni, M., Elpidorou, M., Kroon, A. M., & Taanman, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-61381-9 · Cited by 96
Mitochondrial DNA mutations in ageing and cancer
Smith, A. L. M., Whitehall, J. C., & Greaves, L. C. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13291 · Cited by 112
Exploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells
Nguyen, C. C., & Pandey, S. (2019) · Cancers · doi:10.3390/cancers11070916 · Cited by 103
Qureshi-Baig, K., Ullmann, P., Haan, S., & Letellier, E. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0602-2 · Cited by 109
Horizontal transfer of mitochondria between mammalian cells: beyond co-culture approaches
Berridge, M. V., McConnell, M. J., Grasso, C., Bajzíková, M., Kovářová, J., & Neužil, J. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.04.003 · Cited by 93
Selected mitochondrial DNA landscapes activate the SIRT3 axis of the UPRmt to promote metastasis
Kenny, T. C., Hart, P. C., Ragazzi, M., Sersinghe, M., Chipuk, J. E., Sagar, M. A. K., Eliceiri, K. W., LaFramboise, T., Grandhi, S., Santos, J. H., et al. (2017) · Oncogene · doi:10.1038/onc.2017.52 · Cited by 96
A Review on Annona muricata and Its Anticancer Activity
Ilango, S., Sahoo, D. K., Paital, B., Kathirvel, K., Gabriel, J. I., Subramaniam, K., Jayachandran, P., Dash, R. K., Hati, A. K., Behera, T. R., et al. (2022) · Cancers · doi:10.3390/cancers14184539 · Cited by 91
Metabolic heterogeneity and plasticity of glioma stem cells in a mouse glioblastoma model
Shibao, S., Minami, N., Koike, N., Fukui, N., Yoshida, K., Saya, H., & Sampetrean, O. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox170 · Cited by 102
Saito, K., Zhang, Q., Yang, H., Yamatani, K., Ai, T., Ruvolo, V. R., Baran, N., Cai, T., Ma, H., Jacamo, R. O., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003661 · Cited by 101
Synthetic Lethal Vulnerabilities in KRAS-Mutant Cancers
Aguirre, A. J., & Hahn, W. C. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031518 · Cited by 90
“…an inducible KrasG12D (iKras) mouse model of pancreatic cancer, Draetta and colleagues have demonstrated that metabolic reprogramming from a decreased reliance on glycolysis to a strong dependence on oxidative phosphorylation enables survival in the absence of KRAS signaling (Viale et al. 2014).”
BackgroundAvolio, R., Matassa, D. S., Criscuolo, D., Landriscina, M., & Esposito, F. (2020) · Biomolecules · doi:10.3390/biom10010135 · Cited by 90
Mitochondrial DNA heteroplasmy in human health and disease
Stefano, G. B., & Kream, R. M. (2016) · Biomedical Reports · doi:10.3892/br.2016.590 · Cited by 100
Norberg, E., Lako, A., Chen, P.-H., Stanley, I. A., Zhou, F., Ficarro, S. B., Chapuy, B., Chen, L., Rodig, S. J., Shin, D. H., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.116 · Cited by 96
Mitochondrial Dysfunction at the Center of Cancer Therapy
Chiu, H. Y., Tay, E. X. Y., Ong, D. S. T., & Taneja, R. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7898 · Cited by 95
Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response
McCann, E., O'Sullivan, J. N., & Marcone, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100905 · Cited by 93
Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic Inflammation
Yang, S., Imamura, Y., Jenkins, R. W., Cañadas, I., Kitajima, S., Aref, A., Brannon, A., Oki, E., Castoreno, A., Zhu, Z., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0235 · Cited by 89
Self-citationThe SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression
Ma, B., Cheng, H., Mu, C., Geng, G., Zhao, T., Luo, Q., Ma, K., Chang, R., Liu, Q., Gao, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08618-y · Cited by 89
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2016) · Clinical and Translational Medicine · doi:10.1186/s40169-016-0082-9 · Cited by 100
Subedi, A., Liu, Q., Ayyathan, D. M., Sharon, D. M., Cathelin, S., Hosseini, M., Xu, C., Voisin, V., Bader, G. D., D’Alessandro, A., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2021.06.004 · Cited by 103
Characterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy
Ding, C., Shan, Z., Li, M., Chen, H., Li, X., & Jin, Z. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.02.010 · Cited by 109
Baek, M. L., Lee, J., Pendleton, K. E., Berner, M. J., Goff, E. B., Tan, L., Martinez, S. A., Mahmud, I., Wang, T., Meyer, M. D., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02596-8 · Cited by 94
Baulies, A., Montero, J., Matías, N., Insausti-Urkia, N., Terrones, O., Basáñez, G., Vallejo, C. G., de la Rosa, L. C., Martínez-Gili, L., Robles, D., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.08.022 · Cited by 93
Wen, Y., Xiong, X., Scott, T. L., Li, A. T., Wang, C., Weiss, H. L., Tan, L., Bradford, E. M., Fan, T. W. ‐., Chandel, N. S., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-018-0265-6 · Cited by 89
Impaired Mitochondrial ATP Production Downregulates Wnt Signaling via ER Stress Induction
Costa, R., Peruzzo, R., Bachmann, M., Montà, G. D., Vicario, M., Santinon, G., Mattarei, A., Moro, E., Quintana–Cabrera, R., Scorrano, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.050 · Cited by 93
Seth, S., Li, C.-Y., Ho, I.-L., Corti, D., Loponte, S., Sapio, L., Del Poggetto, E., Yen, E.-Y., Robinson, F. S., Peoples, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.048 · Cited by 84
Self-citationLi, J., Agarwal, E., Bertolini, I., Seo, J. H., Caino, M. C., Ghosh, J. C., Kossenkov, A. V., Liu, Q., Tang, H., Goldman, A. R., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz8240 · Cited by 87
Is Reliance on Mitochondrial Respiration a “Chink in the Armor” of Therapy-Resistant Cancer?
Wolf, D. A. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.001 · Cited by 85
Mitochondrial dynamics and metastasis
Altieri, D. C. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2961-2 · Cited by 92
Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies
Ricci, J., & Chiche, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00556 · Cited by 90
Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8313 · Cited by 83
“This conforms to findings in pancreatic cancer, in which reliance on mitochondrial respiration and impaired glycolytic function have been described as hallmarks of a subpopulation of quiescent tumor cells that survive extinction of KRAS oncogenic signals and are eventually responsible for tumor relapse (23).”
BackgroundMetabolic pathway analysis using stable isotopes in patients with cancer
Bartman, C., Faubert, B., Rabinowitz, J. D., & DeBerardinis, R. J. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00632-z · Cited by 99
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Reyes‐Castellanos, G., Masoud, R., & Carrier, A. (2020) · Biomedicines · doi:10.3390/biomedicines8080270 · Cited by 88
Defueling the cancer: ATP synthase as an emerging target in cancer therapy
Wang, T., Ma, F., & Qian, H. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.08.015 · Cited by 91
Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer
Sriramkumar, S., Sood, R., Huntington, T. D., Ghobashi, A. H., Vuong, T. T., Metcalfe, T. X., Wang, W., Nephew, K. P., & O’Hagan, H. M. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03447-y · Cited by 94
Pettazzoni, P., Viale, A., Shah, P., Carugo, A., Ying, H., Wang, H., Genovese, G., Seth, S., Minelli, R., Green, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1854 · Cited by 81
Self-citationMitochondrial Flexibility of Breast Cancers: A Growth Advantage and a Therapeutic Opportunity
Avagliano, A., Ruocco, M. R., Aliotta, F., Belviso, I., Accurso, A., Masone, S., Montagnani, S., & Arcucci, A. (2019) · Cells · doi:10.3390/cells8050401 · Cited by 93
Ravichandran, M., Hu, J., Cai, C., Ward, N. P., Venida, A., Foakes, C., Kuljanin, M., Yang, A., Hennessey, C. J., Yang, Y., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0044 · Cited by 80
Metadata
- Authors
- Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A. K., Kapoor, A., Yao, W., Brunetto, E., Kang, Y., Yuan, M., Asara, J. M., Wang, Y. A., Heffernan, T. P., Kimmelman, A. C., Wang, H., Fleming, J. B., Cantley, L. C., DePinho, R. A., & Draetta, G. F.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Weill Cornell Medicine (US)
- IRCCS Ospedale San Raffaele (IT)
- Beth Israel Deaconess Medical Center (US)
- Dana-Farber Cancer Institute (US)
- Corresponding author
- Viale, Andrea
- Draetta, Giulio F.
- ORCID
- Viale, Andrea
- Pettazzoni, Piergiorgio
- Lyssiotis, Costas A.
- Ying, Haoqiang
- Sánchez, Nora
- Marchesini, Matteo
- Carugo, Alessandro
- Seth, Sahil
- Giuliani, Virginia
- Colla, Simona
- Nezi, Luigi
- Genovese, Giannicola
- Deem, Angela K.
- Yao, Wantong
- Brunetto, Emanuela
- Kang, Ya’an
- Yuan, Min
- Asara, John M.
- Wang, Y. Alan
- Heffernan, Timothy P.
- Kimmelman, Alec C.
- Wang, Huamin
- Fleming, Jason B.
- Cantley, Lewis C.
- DePinho, Ronald A.
- Draetta, Giulio F.
- Venue
- Nature
- Published
- 2014-08-10
- Volume
- 514
- Issue
- 7524
- Pages
- 628-632
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4376130
- OpenAlex
- W2023300506
- Semantic Scholar
- 819eeeb41f6e84dd5c00221a269e91238736c4ad
- Cited by
- 1,259
- References
- 125
- Citations by year
- 2026: 93 · 2025: 72 · 2024: 104 · 2023: 105 · 2022: 119 · 2021: 131 · 2020: 135 · 2019: 114 · 2018: 105 · 2017: 90 · 2016: 99 · 2015: 81 · 2014: 8
- FWCI
- 44.61
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-04-08)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P50CA127003, CA-16672, CA 016672, P01CA120964, P30CA016672, P01CA117969)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- pancreatic ductal adenocarcinoma, KRAS mutation, tumor recurrence, oxidative phosphorylation, mitochondrial respiration, cancer stem cells, autophagy, glycolysis, OXPHOS inhibitors, combination therapy
- MeSH terms
- Animals, Autophagy, Cell Survival, Disease Models, Animal, Female, Glycolysis, Lysosomes, Mitochondria, Mutation, Neoplasm Recurrence, Local, Oxidative Phosphorylation, Pancreatic Neoplasms, Recurrence, Neoplastic Stem Cells, Signal Transduction, Gene Expression Regulation, Neoplastic, Genes, p53, Proto-Oncogene Proteins p21(ras), Cell Respiration, Carcinoma, Pancreatic Ductal, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.